People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Scout Bio, Inc. | — | Biotech / Pharma | Series B | $34.0M | $104.3M | 2018 |
| Goldilocks Therapeutics, Inc. | — | Biotechnology | Seed | $1.2M | $54.7M | 2019 |
Krishna Polu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Krishna Polu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Heron | 1 | 11 |
| Scott Minick | 1 | 7 |
| Nancy Hong | 1 | 4 |
| Kevin Mahoney | 1 | 3 |
| Tadataka Yamada | 1 | 2 |
| Arthur Klausner | 1 | 2 |
| Remy Durand | 1 | 1 |
| Damian Lismore | 1 | 1 |
| Cindy Cole | 1 | 1 |
| Mark Hefferman | 1 | 1 |
| Aditya Kohli | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.